An interventional study of Ultrasound-Guided Pulsed Radiofrequency Treatment and Ultrasound-Guided 5% Dextrose Injection in Chronic Plantar Fasciitis, Chronic Heel Pain and Foot Pain, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment
Among 42 studies in Fasciitis, Plantar with a site in Turkey — 15 open to participants now, 16 under way, none of them phase 3. Fasciitis, Plantar · Turkey.
Among the 42 studies in Fasciitis, Plantar with a site in Turkey, this one is the 17th largest by planned enrollment of the 28 interventional ones that give a count, is one of 9 that started in 2026, is one of 28 with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 36th registered.
223 studies on the registry are indexed under Fasciitis, Plantar; 58 are open to participants now.
This study's planned enrollment of 50 is below the median of 56 across 194 interventional studies indexed under Fasciitis, Plantar.
Browse Fasciitis, Plantar studies →15 of the 42 studies in Fasciitis, Plantar with a site in Turkey are open now, in 1 country. Each count lists the studies.
Of the 29 Fasciitis, Plantar studies recruiting now, 5 (17%) set no upper age limit and 21 (72%) stop at 75 or younger; 0 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →42 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 9 started in 2026.
Median enrollment 57 across the 28 interventional studies, 77 across the 14 observational. Of the 22 that completed or were terminated, 1 (5%) have results posted.
None of the 42 has an industry lead sponsor. The 10 most frequent:
Ankara City Hospital Bilkent is the lead sponsor of 443 studies on the registry; 111 are open to participants now.
Ankara City Hospital Bilkent has 3 studies filed under Fasciitis, Plantar — fewer than ten, so there is no comparison to draw.
8 of the studies in Fasciitis, Plantar with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07628218Balikesir Ataturk City HospitalVideo-Based Versus Physician-Led Exercise Training for Plantar Fasciitis | 2026-11-12 |
| NCT07761000Ahi Evran University Education and Research HospitalEvaluation of Spinal Posture, Balance, and Core Muscle Endurance in Individuals With Plantar Fasciitis | 2026-12-01 |
| NCT07878273Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyTibial Nerve Size and Clinical Features in Chronic Plantar Fasciitis | 2026-12-01 |
| NCT07754214Karamanoğlu Mehmetbey UniversityOutcomes of the Proprioception and Strengthening Exercise Program in Chronic Plantar Fasciitis | 2026-12-31 |
| NCT07688876Ankara City Hospital BilkentPulsed Radiofrequency Versus 5% Dextrose Injection in Chronic Plantar Fasciitis | 2027-01-01 |
Among the 42 studies in Fasciitis, Plantar with a site in Turkey, from their registry updates:
This prospective, two-center, randomized controlled clinical trial aims to compare the effectiveness of ultrasound-guided pulsed radiofrequency and 5% dextrose injection in patients with chronic plantar fasciitis. Eligible participants will be randomized into two parallel groups. One group will receive ultrasound-guided pulsed radiofrequency treatment, and the other group will receive ultrasound-guided 5% dextrose injection using the peppering technique. All participants will receive a home-based plantar fascia stretching exercise program. Outcomes will be assessed at baseline, 3 weeks, 6 weeks, and 12 weeks after treatment. The primary outcome will be pain intensity measured by the Numeric Rating Scale. Secondary outcomes will include foot function, activity-related pain, ankle-hindfoot function, and health-related quality of life.
Plantar fasciitis is one of the most common causes of chronic heel pain in adults. It may impair walking pattern, daily activities, social life, and work-related functioning. Although conservative treatments are commonly used as first-line therapy, symptoms may become chronic in a considerable proportion of patients.
Dextrose injection is a regenerative injection treatment used in chronic musculoskeletal pain conditions. It is thought to stimulate local tissue healing responses through controlled inflammatory and proliferative mechanisms. Pulsed radiofrequency is a minimally invasive, non-neurodestructive radiofrequency technique used for pain control. Both pulsed radiofrequency and dextrose injection are used in clinical practice for resistant chronic plantar fasciitis; however, comparative data between these two approaches are limited.
This study will be conducted as a prospective, two-center, two-arm, parallel-group randomized controlled trial in the Physical Medicine and Rehabilitation clinics of Ankara Bilkent City Hospital and Adana City Hospital. Participants with chronic plantar fasciitis will be randomized in a 1:1 ratio using the sealed-envelope method. The investigator responsible for randomization will know the allocation, while the outcomes assessor will be blinded to treatment allocation. Blinding of the interventionists will not be possible due to the nature of the procedures.
Participants in the pulsed radiofrequency group will receive ultrasound-guided pulsed radiofrequency treatment at baseline. Participants in the 5% dextrose group will receive ultrasound-guided 5% dextrose injection around the medial calcaneal insertion of the plantar fascia using the peppering technique, with 0.1-0.2 mL administered at each entry point. Dextrose injections will be performed in three sessions at 3-week intervals.
All participants will receive a home-based plantar fascia stretching exercise program. Exercises will be demonstrated by a physiotherapist, and participants will be instructed to perform the exercises twice daily for 12 weeks. Participants will be monitored for possible adverse events or complications for at least 30 minutes after the procedure. Clinical outcomes will be assessed at baseline, 3 weeks, 6 weeks, and 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive ultrasound-guided pulsed radiofrequency treatment at baseline. Clinical follow-up assessments will be performed at 3 weeks, 6 weeks, and 12 weeks. All participants will also receive a home-based plantar fascia stretching exercise program.
Procedure: Ultrasound-Guided Pulsed Radiofrequency Treatment
Ultrasound-guided pulsed radiofrequency treatment will be applied for chronic plantar fasciitis. Participants will be monitored for at least 30 minutes after the procedure for possible adverse events or complications.
Procedure: Ultrasound-Guided 5% Dextrose Injection
Ultrasound-guided pulsed radiofrequency treatment will be applied for chronic plantar fasciitis. Participants will be monitored for at least 30 minutes after the procedure for possible adverse events or complications.
Ultrasound-guided 5% dextrose injection will be applied around the medial calcaneal insertion of the plantar fascia using the peppering technique, with 0.1-0.2 mL administered at each entry point. The treatment will consist of three sessions performed at 3-week intervals.
Change in Heel Pain Intensity Assessed by Numeric Rating Scale
Heel pain intensity will be assessed using the Numeric Rating Scale. Resting pain, pain during plantar fascia stretching, and pain with pressure will be evaluated on an 11-point scale from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.
Time frame: Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Change in Activity-Related Pain Assessed by the Roles and Maudsley Score
Activity-related heel pain and functional status will be assessed using the Roles and Maudsley Score. The score ranges from 1 to 4, with lower scores indicating better clinical status and higher scores indicating worse pain and functional limitation.
Time frame: Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Change in Foot Function Assessed by the Foot Function Index
Foot-related pain, disability, and activity limitation will be assessed using the Foot Function Index. The scale includes pain, disability, and activity limitation subscales. Scores are converted to a 0-100 scale, with higher scores indicating greater pain, disability, and activity limitation.
Time frame: Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Change in Ankle-Hindfoot Function Assessed by the American Orthopaedic Foot and Ankle Society Score
Ankle-hindfoot function will be assessed using the American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Score. The score evaluates pain, function, and alignment. The total score ranges from 0 to 100, with higher scores indicating better ankle-hindfoot function.
Time frame: Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Change in Health-Related Quality of Life Assessed by the Nottingham Health Profile
Health-related quality of life will be assessed using the Nottingham Health Profile. The questionnaire includes six domains: energy level, pain, emotional reactions, sleep, social isolation, and physical activity. The total score ranges from 0 to 600, with higher scores indicating worse perceived health status.
Time frame: Baseline, 3 weeks, 6 weeks, and 12 weeks after treatment
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.
Of 104 non-industry interventional studies with no phase under Fasciitis, Plantar, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 21. This study's planned 12 months is close to that.
Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 6 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara City Hospital Bilkent →